Description
Goserelin is among others, authorised for patients with advanced prostate cancer where an endocrine treatment is indicated. It is an LHRH agonist (analogue of the natural luteinizing hormone-releasing hormone) and suppresses the serum testosterone to castration level to inhibit the growth of hormonedepending prostate carcinoma.
Goserelin acetate is approved to treat:
- Breast cancer that is advanced. It is used as palliative treatment in premenopausal and perimenopausal women.
- Prostate cancer. It is used with flutamide and radiation therapy in localized prostate cancer. It is also used as palliative treatment in advanced prostate cancer.
Goserelin acetate is also being studied in conditions related to cancer.